This content is in French.
IAVI G004 trial: overview of a next generation HIV vaccine
5 février 2026
By Carolina Lima | Published on February 5, 2026 | 3 min readHIV remains one of the most challenging viruses to prevent because it mutates quickly and can hide from the immune system. Even though treatments have improved greatly, creating a vaccine that works against the many versions of HIV has been extremely difficult. On January 6, 2026, the International AIDS Vaccine Initiative (IAVI)—an inter
By Carolina Lima | Published on February 5, 2026 | 3 min read
HIV remains one of the most challenging viruses to prevent because it mutates quickly and can hide from the immune system. Even though treatments have improved greatly, creating a vaccine that works against the many versions of HIV has been extremely difficult.
On January 6, 2026, the International AIDS Vaccine Initiative (IAVI)—an international nonprofit organization focused on developing vaccines and antibody‑based tools to stop HIV—published a press release announcing the launch of the IAVI G004 Phase 1 HIV vaccine trial. The first vaccinations were given on December 15, 2025, in South Africa, a country well‑known for its strong HIV research programs and high need for new prevention options.
HIV remains one of the most challenging viruses to prevent because it mutates quickly and can hide from the immune system. Even though treatments have improved greatly, creating a vaccine that works against the many versions of HIV has been extremely difficult.
On January 6, 2026, the International AIDS Vaccine Initiative (IAVI)—an international nonprofit organization focused on developing vaccines and antibody‑based tools to stop HIV—published a press release announcing the launch of the IAVI G004 Phase 1 HIV vaccine trial. The first vaccinations were given on December 15, 2025, in South Africa, a country well‑known for its strong HIV research programs and high need for new prevention options.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
International AIDS Vaccine Initiative (IAVI). IAVI announces first vaccinations in IAVI G004, a Phase 1 clinical trial of a promising HIV vaccine approach. Press release. January 6, 2026.
View the source
